Preferred Label : HER2 Inhibitor IAM1363;
NCIt definition : An orally bioavailable, immediate release (IR) capsule formulation containing a selective
and irreversible inhibitor of the receptor tyrosine kinase human epidermal growth
factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon
oral administration, HER2 inhibitor IAM1363 selectively targets, irreversibly binds
to and inhibits the activity of wild-type (WT) and various HER2 mutants. This prevents
HER2-mediated signaling and may lead to cell death in HER2-expressing tumor cells.
HER2, a receptor tyrosine kinase overexpressed on a variety of tumor cell types, plays
an important role in tumor cell proliferation and tumor vascularization. IAM1363 is
able to penetrate the blood-brain -barrier (BBB) and may be used in HER2-expressing
brain tumors and brain metastases. IAM1363 does not inhibit epidermal growth factor
receptor (EGFR) and avoids off-target EGFR-mediated toxicity.;
Molecule name : IAM-1363; IAM-H1; ENT-H1; IAM 1363;
NCI Metathesaurus CUI : CL1927035;
Origin ID : C204809;
UMLS CUI : C5908067;
Semantic type(s)
- concept_is_in_subset
- has_target
